NO930174L - Maalspesifikke antistoff-superantigenkonjugater samt fremstilling derav - Google Patents

Maalspesifikke antistoff-superantigenkonjugater samt fremstilling derav

Info

Publication number
NO930174L
NO930174L NO93930174A NO930174A NO930174L NO 930174 L NO930174 L NO 930174L NO 93930174 A NO93930174 A NO 93930174A NO 930174 A NO930174 A NO 930174A NO 930174 L NO930174 L NO 930174L
Authority
NO
Norway
Prior art keywords
conjugate
cells
preparation
lysis
specific antibody
Prior art date
Application number
NO93930174A
Other languages
English (en)
Other versions
NO930174D0 (no
NO312816B1 (no
Inventor
Terje Kalland
Gunnar Hedlund
Mikael Dohlsten
Peter Lando
Eva Akerblom
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9002479A external-priority patent/SE9002479D0/xx
Priority claimed from SE9002484A external-priority patent/SE9002484L/xx
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of NO930174D0 publication Critical patent/NO930174D0/no
Publication of NO930174L publication Critical patent/NO930174L/no
Publication of NO312816B1 publication Critical patent/NO312816B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
NO19930174A 1990-07-20 1993-01-19 Fremgangsmåte ved fremstilling av antistoff- superantigenkonjugater NO312816B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9002479A SE9002479D0 (sv) 1990-07-20 1990-07-20 Antibody conjugates
SE9002484A SE9002484L (sv) 1990-07-20 1990-07-20 Nya substituerade polyetrar
PCT/SE1991/000496 WO1992001470A1 (en) 1990-07-20 1991-07-16 Target specific antibody-superantigen conjugates and their preparation

Publications (3)

Publication Number Publication Date
NO930174D0 NO930174D0 (no) 1993-01-19
NO930174L true NO930174L (no) 1993-01-19
NO312816B1 NO312816B1 (no) 2002-07-08

Family

ID=26660818

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19930174A NO312816B1 (no) 1990-07-20 1993-01-19 Fremgangsmåte ved fremstilling av antistoff- superantigenkonjugater

Country Status (16)

Country Link
EP (1) EP0610179B1 (no)
JP (1) JP3334130B2 (no)
KR (1) KR100189024B1 (no)
AT (1) ATE144145T1 (no)
AU (1) AU656906B2 (no)
CA (1) CA2087164C (no)
DE (1) DE69122777T2 (no)
DK (1) DK0610179T3 (no)
ES (1) ES2094231T3 (no)
GR (1) GR3022202T3 (no)
HK (1) HK1007955A1 (no)
HU (1) HU218603B (no)
LV (1) LV10201B (no)
NO (1) NO312816B1 (no)
RU (1) RU2125889C1 (no)
WO (1) WO1992001470A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6042837A (en) * 1989-09-20 2000-03-28 Kalland; Terje Methods of staphylococcal enterotoxin directed cell-mediated cytotoxicity (SDCC)
US6126945A (en) 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US6197299B1 (en) 1990-07-20 2001-03-06 Pharmacia & Upjohn Ab Antibody conjugates
GB9114399D0 (en) * 1991-07-03 1991-08-21 Ici Plc Conjugates
SE9102074D0 (sv) * 1991-07-03 1991-07-03 Kabi Pharmacia Ab Tomour antigen specific antibody
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
PT627940E (pt) * 1992-03-05 2003-07-31 Univ Texas Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
EP0659438A1 (en) * 1993-12-23 1995-06-28 Boehringer Mannheim Gmbh Conjugates consisting of peptidic T cell antigens and cell binding groups, and their use for therapy
GB9326574D0 (en) * 1993-12-31 1994-03-02 King S College London Dry power inhalers
SE9402430L (sv) * 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
US6103236A (en) 1995-05-10 2000-08-15 Kyowa Hakko Kogyo Co., Ltd. Toxin conjugates
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
IL140700A0 (en) 1998-07-13 2002-02-10 Univ Texas Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US4797491A (en) * 1986-03-17 1989-01-10 Cetus Corporation Compound 1-(3-(2-pyridyldithio)propionamido)-12-(5-hydrazidoglutaramido)-4,9-dioxadodecane
US4806494A (en) * 1986-07-24 1989-02-21 The United States Of America As Represented By The Department Of Health & Human Services Monoclonal antibody against ovarian cancer cells (OVB-3)
GB8626413D0 (en) * 1986-11-05 1986-12-03 Gilliland L K Antibodies
US4981979A (en) * 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
US5004692A (en) * 1987-12-15 1991-04-02 Protein Design Labs, Inc. Cloning and expression of phosopholipase C genes
IL89504A0 (en) * 1988-03-08 1989-09-10 Univ Wyoming Diphtheria toxin derivative,process for the preparation thereof and pharmaceutical composition containing the same
EP0334300A1 (en) * 1988-03-21 1989-09-27 Neorx Corporation The use of monoclonal antibodies and conjugates thereof as signals to direct sensitized effector cells to tumor sites
JPH02196799A (ja) * 1988-04-08 1990-08-03 Agency Of Ind Science & Technol 抗ヒト癌蛋白複合体

Also Published As

Publication number Publication date
CA2087164C (en) 2002-11-26
HK1007955A1 (en) 1999-04-30
DK0610179T3 (da) 1997-03-24
ATE144145T1 (de) 1996-11-15
WO1992001470A1 (en) 1992-02-06
DE69122777T2 (de) 1997-04-10
EP0610179A1 (en) 1994-08-17
GR3022202T3 (en) 1997-03-31
LV10201B (en) 1995-08-20
ES2094231T3 (es) 1997-01-16
EP0610179B1 (en) 1996-10-16
HU9300148D0 (en) 1993-04-28
HUT67502A (en) 1995-04-28
HU218603B (hu) 2000-10-28
NO930174D0 (no) 1993-01-19
AU656906B2 (en) 1995-02-23
NO312816B1 (no) 2002-07-08
JPH05508856A (ja) 1993-12-09
RU2125889C1 (ru) 1999-02-10
KR100189024B1 (ko) 1999-06-01
CA2087164A1 (en) 1992-01-21
LV10201A (lv) 1994-10-20
AU8294191A (en) 1992-02-18
JP3334130B2 (ja) 2002-10-15
DE69122777D1 (de) 1996-11-21

Similar Documents

Publication Publication Date Title
NO930174L (no) Maalspesifikke antistoff-superantigenkonjugater samt fremstilling derav
CY1105500T1 (el) Αντιγονο και εμβολιο απο staphylococcus
OA07388A (fr) Nouveaux conjugués associant, par liaison convalente, une enzyme et un anticorps et associations médicamenteuses utilisant lesdits conjugués.
IL59917A (en) Monoclonal antibody of class igg to normal human t cells and cutaneous t lymphoma cells,its preparation and pharmaceutical and diagnostic compositions containing it
CA2078118A1 (en) Cc-1065 analogs
RU95112465A (ru) Пирановые соединения, фармацевтическая композиция, способ получения и промежуточные соединения
CA2124218A1 (en) Cytotoxic drug therapy
DK0693132T3 (da) Rapamycinassay
RU93004918A (ru) Новые конъюгаты антитело-суперантиген, способ их получения, способ лизирования клетки-мишени, способ лечения и использование конъюгатов для получения фармкомпозиции
DE69119074D1 (de) Kovalente-ther lipidnukleosid-konjugate
ES2137310T3 (es) Vacuna contra una infeccion por streptococcus suis.
NO920942D0 (no) Konjugert vaksine for gruppe b streptococcus
WO2005108430A3 (en) Monoclonal antibody sc104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent
AU6628386A (en) Ricin-antibody conjugates
WO2002038611A3 (en) Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins
Kitagawa et al. Biosynthesis of rat liver carbamoylphosphate synthetase I on cycloheximide-sensitive ribosomes
CA2141025A1 (en) Anti-mucus glycoprotein monoclonal antibody
CA2156397A1 (en) Rapamycin assay
TH11834EX (th) แอนติบอดีสังยุค
TH13782EX (th) คู่สังยุคชนิดใหม่สำหรับการให้กรดนิวคลีอิคเข้าสู่เซลล์ยูคารีโอทชั้นสูง